Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying imatinib mesylate to see how well it works in treating
patients with chronic myelogenous leukemia. Imatinib mesylate may stop the growth of cancer
cells by blocking the enzymes necessary for cancer cell growth